Chronic Idiopathic Constipation Drugs Market at a CAGR over 7% during 2016-2022

Posted by David Colin on December 29th, 2017

The latest market report published by Credence Research, Inc. “Global Chronic Idiopathic Constipation (CIC) Drugs Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022,” the chronic idiopathic constipation (CIC) drugs market was valued at USD 1675.4 Mn in 2015, and is expected to reach USD 2570.8 Mn by 2022, expanding at a CAGR of 6.4% from 2016 to 2022; where Europe has the largest market share.

Browse the full report at

Market Insights
Chronic idiopathic constipation (CIC) is a common gastrointestinal disorder. The currently available treatment options, both prescription based and OTC have demonstrated limited efficacy in a considerable set of patients. Thus there is a major demand for more effective medications for the treatment of CIC. Linaclotide is a secretagogue and has novel action mechanism; it has low oral bioavailability and has demonstrated the least systemic side effects. Through several clinical trials, Linaclotide has demonstrated greater efficacy in treating both CIC and irritable bowel syndrome induced constipation.

Currently North America is the largest regional market for CIC drugs at a market share of approximately 50%. It is also expected that the region will progress at the fastest CAGR of above 8% during the forecast period. Higher awareness among physicians and patient population significantly contribute the market growth in the region. Earliest commercialization of the drug in the US also adds up to the high demand of the drug in North America market. On the other hand, gradual introduction of Linaclotide in other developing markets will facilitate market growth in Asia Pacific market. China, Japan, Australia and India are the major national markets that are expected to give highest revenue contributions to the Asia Pacific CIC drugs market. Also, supporting the established fact of correlation between age and risk of CIC, it is reported that China and Japan will be the largest national markets for CIC drugs in Asia Pacific.

Overall, the CIC drugs market is open for further innovations, anticipating introduction of novel therapeutic options in the global market. Intensive research and development activities undertaken by the major market players indicate further competition in the market in the next ten years.

Chapter 1 Preface
1.1 Report Scope and Description
1.2 Research Methodology

Chapter 2 Executive Summary

Browse For The Sample Page @

Chapter 3 Global CIC Drugs Market Analysis
3.1 CIC Drugs Market Overview
3.2 Market Inclination Insights
3.3 Attractive Investment Proposition, 2015
3.4 Market Dynamics
3.4.1 Drivers Adverse health effects from modern dietary habits Cancer or other systematic disease Increasing geriatric population Better and effective drugs in pipeline Increasing constipation problems as a side-effect frequently prescribed medicines
3.4.2 Restraints Surgical treatments Unawareness and Ignorance among people Side-effects of the chronic idiopathic constipation drugs
3.4.3 Opportunities Emerging APAC market High unmet needs
3.5 Attractive Investment Proposition, 2015
3.6 Market Positioning of Key CIC Drugs Manufacturers

Company Profiles

About Us:

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.


Name: Chris Smith

Designation: Global Sales Manager


Ph: 1-800-361-8290


Like it? Share it!

David Colin

About the Author

David Colin
Joined: September 8th, 2017
Articles Posted: 147

More by this author